Folic-acid-conjugated pullulan/poly(DL-lactide-co-glycolide) graft copolymer nanoparticles for folate-receptor-mediated drug delivery
© Lee et al.; licensee Springer. 2015
Received: 18 November 2014
Accepted: 23 December 2014
Published: 6 February 2015
Nanoparticles have been extensively investigated for targeted delivery of anticancer drugs. Since the folate receptor is universally over-expressed on the tumor cell membrane, folic acid is often used to modify the fate of nanoparticles in biologicals.
To fabricate targetable nanoparticles, folic acid was conjugated to a pullulan backbone and poly(DL-lactide-co-glycolide) (PLGA) (abbreviated as FAPuLG) was conjugated. KB cells and NIH3T3-cell-bearing mice were prepared to prove folate receptor targeting of FAPuLG nanoparticles.
Results and discussion
Nanoparticles of FAPuLG copolymer that self-assembled in water were small with diameters <200 nm. Doxorubicin (DOX) as a model drug was incorporated into the FAPuLG nanoparticles that were used to treat folate receptor over-expressing KB human carcinoma cells. Fluorescence microscopy revealed that DOX-incorporated FAPuLG nanoparticles induced strong red fluorescence in the KB cells in the absence of folic acid. However, fluorescence intensity was decreased by blocking folate receptors. Antitumor activity of FAPuLG nanoparticles against KB cells in vitro was also decreased by blocking folate receptors. In animal study using near-infrared dye-conjugated FAPuLG nanoparticles, fluorescence intensity was significantly higher at KB solid tumor than that of NIH3T3.
The results indicate that FAPuLG nanoparticles can target the folate receptor of tumor cells. FAPuLG nanoparticles are a promising candidate for active targeting of anticancer agents.
KeywordsFolate receptor Pullulan Nanoparticles KB cells Drug targeting
Nanoparticle-based targeted drug delivery systems have been extensively investigated for biomedical applications [1-4]. The unique features of nanoscale carriers are their huge surface area versus volume, ease of surface modification, prolonged circulation in the blood through avoidance of the reticuloendothelial system, and small size that facilitates specific interaction with cell surface receptors, enabling the targeting of specific cells or tissues having disease in the specific organs [1,2,5-10]. Furthermore, tumor-specific targeting of nanoparticles allows the killing of tumor cells selectively without harm to healthy tissues or cells [6-8].
Since nanoparticles themselves do not possess tumor specificity, various kinds of tumor-specific ligand such as endothelial growth-factor-related peptide , hyaluronic acid , galactose , folic acid , monoclonal antibody , and transferrin  have been used to bestow tumor-specific drug targeting of nanoparticles. Among them, the folate receptor is over-expressed in virtually all types of tumor cells, while being barely detectable in healthy tissues and cells [11-13]. Folic-acid-anchored nanoparticles have tumor-specific targeting of anticancer drug via folate receptors [13,14]. One study reported that doxorubicin (DOX)-encapsulated nanoparticles having folic acid on the particle surface were remarkably efficient for the regression of tumor growth and reduction of toxicity compared to free DOX or plain nanoparticles . Furthermore, nanoparticles having folic acid as a targeting moiety facilitate accumulation of anticancer agents in tumors .
In this study, folic-acid-conjugated pullulan-g-poly(DL-lactide-co-glycolide) (PLGA) (abbreviated as FAPuLG) copolymers were synthesized for targeted delivery of a model anticancer agent (DOX) to tumor cells. The advantages of pullulan include biocompatibility, immuno-neutrality, and numerous functional hydroxyl groups [15,16]. Hence, pullulan can be used as a drug-carrying material and its derivatives, such as pullulan/PLGA graft copolymer, can be considered as an ideal vehicle for fabrication of drug-targeting carriers.
We previously reported that PuLG copolymer can self-assemble in an aqueous environment to form small nanospheres <100 nm in diameter, which are useful as a drug-delivery carrier . Physicochemical properties of nanoparticles of FAPuLG were studied and their targeting potential was assessed using KB tumor cells in vitro.
Pullulan (Mn 67,500) and PLGA 5005 (Mn 8,200) were purchased from Wako Pure Chemical Industries, Osaka, Japan. Folic acid, N,N′-dicyclohexyl carbodiimide (DCC) and 4-(N,N-dimethylamino)pyridine (DMAP) were purchased from Aldrich Chemical (St. Louis, MO, USA). DOX HCl and triethyleamine (TEA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Spectra/Pro™ dialysis membranes with a molecular weight cutoff (MWCO) of 6,500 g/mol were purchased from Spectrum Laboratories (Rancho Dominguez, CA, USA). Sulfo-cyanine 5 carboxylic acid was purchased from Lumiprobe Co. (Florida, USA). Dichloromethane (DCM) and dimethyl sulfoxide (DMSO) of high-performance liquid chromatography grade were dried with CaH2 then distilled prior to use. 1H nuclear magnetic resonance (NMR) spectra were recorded in deuterated solvents (DMSO-d6) at a concentration of 30 mg/0.6 ml using a model AMX-300 apparatus (Bruker, Billerica, MA, USA).
Synthesis of folic-acid-conjugated copolymer
Pullulan (675 mg) was dissolved in DMSO (15 ml) for 3 h. Folic acid was dissolved in DMSO (5 ml) with a 1.1 equivalent amount of DCC and DMAP for 30 min. Folic acid solution was added into the pullulan solution and stirred for 24 h in a nitrogen atmosphere. The resulting solution was filtered to remove by-products and dialyzed against deionized water for 3 days, followed by lyophilization. The synthesized folic acid-pullulan (FA-PU) conjugates were analyzed with NMR. FA-Pu-PLGA (abbreviated as FAPuLG) copolymers were synthesized as follows. Three hundred milligrams of FA-PU and 182 mg of PLGA were dissolved separately in dried DMSO. A 1.2 equivalent amount DCC in DMSO solution was added to the PLGA/DMSO solution, which was stirred for 30 min to activate the carboxyl group of the PLGA. The resulting solution was added to the pullulan/DMSO solution containing 1.2 equivalent amount DMAP, and the reaction was allowed to continue at room temperature for 24 h. The reaction mixture was filtered to remove the by-products and exhaustively dialyzed against deionized water for 3 days. The dialyzed solution was lyophilized for 3 days, and the solid product was precipitated three times in DCM to remove unreacted PLGA and dried in a vacuum oven for 2 days. The substitution degree of folic acid and PLGA was calculated from molecular weight of pullulan and PLGA . PuLG copolymer was synthesized as described previously . The number-average molecular weight (Mn) of synthesized copolymers was analyzed using 1H NMR spectroscopy. The molecular weight (M.W.) of pullulan and PLGA was analyzed using gel permeation chromatography as reported previously . The weight average M.W. (Mw), Mn, and polydispersity of pullulan were 67,500, 62,400, and 1.081, respectively. The Mw, Mn, and polydispersity of PLGA were 8,200, 5,800, and 1.41, respectively.
Near-infrared absorption dye (NIR dye) conjugation was performed as follows: 20 mg of FAPuLG copolymer was dissolved in dry DMSO. To this solution, 1 mg of sulfo-cyanine 5 carboxylic acid with equivalent mole of DCC and DMAP was added and then stirred for 12 h in the room temperature. After that, resulting solution was dialyzed to remove unreacted dye with exchange of water at intervals of 3 h. The dialysis procedure was continued until that dye was not detected. Dye in the dialyzed solution was detected with UV spectrophotometer (UV-1601 UV-VIS spectrophotometer, Shimadzu, Kyoto, Japan) at 642 nm. To evaluate conjugation yield, 3 mg of dye-conjugated polymer was dissolved in DMSO and then the contents of the dye in the polymer were measured with the UV spectrophotometer. For a blank test, polymer without dye was used. Dye contents (%, w/w) = [(Weight of dye in the polymer/total weight of polymer) × 100]. The content of the dye in the polymer was approximately 3.2% (w/w).
Preparation of nanoparticles
Twenty milligrams of PuLG or FAPuLG was dissolved in 3 ml of DMSO. Five milligrams of DOX was separately dissolved in 1 ml of DMSO with trace amounts of TEA and added to the polymer/DMSO solution. The resulting solution was slowly added dropwise to 10 ml of deionized water for 10 min and then loaded into dialysis tubing. The tubing was put into 1 l of deionized water. During dialysis, DOX-loaded nanoparticles formed and organic solvent was removed. Dialysis was continued for 12 h with changes of the water every 2 h. The resulting solution was analyzed or lyophilized. To determine drug contents, 5 mg of lyophilized nanoparticles were dissolved in DMSO, and the absorbance was measured using a UV spectrophotometer (UV-1601 UV-VIS spectrophotometer, Shimadzu, Kyoto, Japan) at 479 nm. Drug contents (%, w/w) were calculated as (amount of DOX in the nanoparticles/weight of nanoparticles) × 100.
Characterization of nanoparticles
Nanoparticle morphology was performed using transmission electron microscopy (TEM) using a JEM-2000 FX II microscope (JEOL, Tokyo, Japan). The diameter of the nanoparticles was measured with a model DLS-7000 dynamic laser scattering apparatus (Otsuka Electronics Company, Osaka, Japan). A sample solution prepared by dialysis was used to determine particle size (concentration 1 mg/ml). The critical association concentration (CAC) of nanoparticles was evaluated with a model RF-5301 fluorescence spectrofluorophotometer (Shimadzu, Tokyo, Japan) as described previously . PuLG or FAPuLG nanoparticles in the absence of a drug were prepared as described above. Polymer (40 mg) was dissolved in DMSO (5 ml) and dialyzed against deionized water for up to 2 days. The nanoparticle suspension was adjusted to various concentrations. The CAC of nanoparticles was estimated using pyrene as a hydrophobic probe. To prepare sample solutions, a known amount of pyrene in acetone was added to each of a series of 20-ml vials, and the acetone was evaporated. The final concentration of pyrene was 6.0 × 10−7 M. To each vial, 10 ml of various concentrations of the nanoparticle suspensions was added, and the solutions were heated for 3 h at 65°C. Equilibration of the pyrene and the PuLG nanoparticles was achieved by allowing the solutions to cool overnight at room temperature. The fluorescence excitation spectra were measured at an emission wavelength of 390 nm. Excitation and emission bandwidths were 1.5 and 1.5 nm, respectively.
Drug release study
Drug release from nanoparticles was carried out at physiological solutions. Five milligrams of nanoparticle solid was reconstituted into 5 ml of deionized water and then introduced into a dialysis tubing. The sealed dialysis tubing was added to a 50-ml Falcon tube containing 40 ml of phosphate-buffered saline (PBS) solutions (pH 7.4, 0.1 M). These tubes were placed in a shaking incubator with a stirring speed of 100 rpm at 37°C. At specific times, the medium was sampled for analysis of drug concentration. Afterwards, the entire medium was replaced with fresh medium to prevent drug saturation. The concentration of drug released was measured using the aforementioned ultraviolet spectrophotometer at 479 nm.
KB human oral squamous carcinoma cells and NIH3T3 mouse fibroblast cells were obtained from the Korean Cell Line Bank (KCLB, Seoul, Korea) and maintained with DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics in a 5% CO2 incubator operating at 37°C.
Targetability of nanoparticles for folate receptor of KB cell
To study targetability of nanoparticles against the folate receptor of tumor cells, KB cells were seeded onto cover glass in 6-well plates and cultured overnight in a 5% CO2 incubator (37°C) with RPMI 1640 media (supplemented with 10% FBS and 1% antibiotics). Cells were washed with PBS (pH 7.4, 0.1 M) and treated with 5 μg/ml of DOX or nanoparticles for 1 h. DOX was dissolved in DMSO and then diluted at least 100 times with folic acid free-RPMI1640 medium. Lyophilized nanoparticles were carefully reconstituted into folic acid free-RPMI1640 medium. To prove targetability of nanoparticles, KB cells were pre-treated with folic acid (5 mM) 1 h before addition of nanoparticles. After 1 h, cells were washed with PBS and treated with 4% paraformaldehyde. Cells were washed again with PBS and fixed by immobilization solution (ImmuMount, Thermo Electron Corporation, Pittsburgh, PA). These cells were observed by confocal laser scanning microscopy (CLSM) using a TCS-SP2 microscope (Leica, Wetzlar, Germany). Flow cytometry analysis of cells was also performed to assess targetability of nanoparticles. KB cells were seeded at a density of 1 × 106 cells in 6-well plates and incubated overnight. Cells were treated with DOX or nanoparticles as described above. After 1 h, cells were harvested and analyzed with a flow cytometer. An excitation wavelength at 488 nm and emission wavelength at 522 nm were used to observe the fluorescence intensity of DOX.
In vitro antitumor activity
Nanoparticle antitumor activity against KB cells were assessed by an established viability assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in vitro. KB cells (3 × 104) were seeded in 96-well plates and incubated overnight in a 5% CO2 incubator at 37°C. DOX or nanoparticles (DOX concentration, 50 μg/ml) were added to wells in the absence or presence of folic acid and then incubated for 4 h. The medium was replaced with a serum-free medium in the absence of folic acid. After 1 day, 25 μl of MTT (2 mg/ml) was added to the 96-well plates and incubated for 4 h. The formazan crystals formed in living cells were solubilized with a sodium dodecyl sulfate (SDS)/HCl solution (SDS, 10% w/v; HCl 0.1 N), and the absorbance was determined at 570 nm using an automated computer-linked microplate reader (Molecular Devices, Sunnyvale, CA, USA).
In vivo fluorescence imaging of NIH3T3 and KB-tumor-bearing mouse
1 × 106 KB cells and 1 × 106 NIH3T3 cells were implanted onto the right side and left side of the back of nude BALb/C mice (5 weeks, 20 g), respectively. Three weeks later, NIR-dye-conjugated nanoparticles (dose: 20 mg/kg, injection volume: 100 μl) were injected intravenously (i.v.) into the tail vein of the mouse. At specific time intervals, the trace of nanoparticles in the mouse was observed with Maestro™ 2 small animal imaging instrument (Cambridge Research and Instruments, Inc., Woburn, MA, USA). After nanoparticle administration (48 h), the mice were sacrificed to observe organ distribution of nanoparticles, and each organ of the mice was also observed with Maestro™ 2 small animal imaging instrument. All animal studies were performed under guidelines of the Committee of Care and Use of Laboratory Animals of Chonnam National University.
Statistical data analysis
The results are expressed as the means of three parallel experiments ± standard deviation. Statistical analysis of the results was performed using the t-test with p < 0.05 as the minimal level of significance.
Characterization of FAPuLG copolymer
Characterization of FAPuLG copolymer
Theoretical ratio a
Experimental ratio c
Characterization of nanoparticles
Characterization of FAPuLG nanoparticles
Average diameter (intensity, nm)
Drug contents (%, w / w )
Folate-receptor-mediated endocytosis and targeting of FAPuLG nanoparticles
Targeted drug delivery using nanoparticles is a promising strategy for treatment of tumor cells [1-13]. Since tumor cells generally over-express various kinds of receptors on the cell membrane, receptor-mediated delivery of bioactive agents is an ideal way to maximize antitumor activity and minimize the unwanted side effect of anticancer drugs. Nanoparticles are an ideal candidate for these purposes because the target ligand can easily be decorated on the large surface area of nanoparticles. Nanoparticles have the unique feature of a small size (around 100-nm diameter), which enables nanoparticle virus-like behavior and passive targeting in the human body . Various target ligands have been developed to decorate the surfaces of colloidal carriers and nanoparticles [5-10]. Among them, folic acid is often selected for tumor targeting of nanoparticulate anticancer drugs because most of tumor cells have numerous folate receptors on the cell surface . Then, targeting to the folate receptor of tumor cells enables nanoparticles to concentrate anticancer drugs in tumor cells and to avoid healthy cells. Zwicke et al. introduced the folate receptor for active targeting of cancer cells using various kinds of nanomaterials . Folic-acid-decorated nanomaterials can be used to various kinds of cancer therapies, such as cancer chemotherapy, cancer imaging, and/or imaging of circulating cancer cells in the human body [8,18,19].
In this study, we used pullulan for conjugation of folic acid and fabrication of nanocarriers of the anticancer drug, DOX. Pullulan, which is a water-soluble, neutral, linear polysaccharide, has properties of biocompatibility and biodegradability. These attributes have been exploited in the extensive biomedical use of pullulan as a nanomaterial [17,20-22]. Since pullulan is highly water-soluble, copolymerization with PLGA endowed amphiphilic properties to copolymers, i.e., pullulan backbone acts as a hydrophilic domain and PLGA acts as a hydrophobic domain . PLGA can form a hydrophobic drug container while pullulan is normally exposed on the surface of nanoparticles. Furthermore, folic acid conjugated with a pullulan backbone also can be exposed on the surface of nanoparticles due to amphiphilicity of FAPuLG copolymer and then used as a targeting ligand for cancer targeting. Figure 4 depicts the self-assembly property of the FAPuLG copolymer in an aqueous environment and the resulting very low CAC values. PuLG and FAPuLG nanoparticles have small particle sizes <200 nm, which allow drug targeting to specific organs and tissues, avoidance of the reticuloendothelial system, prolonged blood circulation, and virus-like behavior . FAPuLG nanoparticles showed targetability against the folate receptor of KB cells (Figure 5), and antitumor activity of DOX was controlled by folate-receptor-mediated drug delivery, indicating that nanoparticles of FAPuLG can be used to deliver an anticancer agent specifically to the folate receptor of tumor cells. Watanabe et al. also reported that folate-polymer conjugate can target the folate receptor of KB cells, with the IC50 of folate-polymer conjugate-coated liposomes being twofold lower than polymer liposomes . We also obtained positive results from the anticancer activity of FAPuLG nanoparticles (Figure 6). DOX-incorporated nanoparticles retained still cytotoxicity against tumor cells even though the folate receptor was blocked. These results might be due to the passive diffusion of drug or nanoparticles into the cells. However, cell viability with treatment of FAPuLG nanoparticles in the presence of folic acid was increased 20% higher than that in the absence of folic acid, indicating that FAPuLG is a promising candidate for active targeting of the folate receptor of tumor cells. Furthermore, we demonstrated that FAPuLG nanoparticles have targetability against KB tumor as shown in Figure 7. Fluorescence imaging study of animals using NIR-dye-conjugated nanoparticles showed that fluorescence intensity was significantly higher in the solid mass of KB tumor cells than in the solid mass of NIH3T3. These results indicated that FAPuLG nanoparticles can specifically target the folic acid receptor of tumor cells. Shen et al. also reported that folic-acid-decorated nanophotosensitizer was highly sensitive for targeting of the folate receptor of KB cells but not for NIH3T3 normal cells . Furthermore, they also described that the viability of NIH3T3 normal cells was not affected by the treatment of nanoparticles regardless of folic acid decoration while viability of KB cancer cells was sensitively decreased according to the presence of folic acid on the nanoparticle surface. Ultimately, folic acid decoration onto the nanoparticles efficiently enhances drug targeting against cancer cell and tumor tissue in vitro/in vivo. We suggest FAPuLG nanoparticles as an ideal candidate for tumor targeting.
In conclusion, we synthesized FAPuLG copolymer and folic-acid-decorated nanoparticles for active tumor targeting. Nanoparticles of FAPuLG copolymer have a small diameter (<200 nm) and targetability to the folate receptor of KB cells. We suggest that FAPuLG copolymer nanoparticles are promising vehicles for drug targeting.
This research was supported by Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology(MEST) (2011-0030034).
- Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2012;48:416–27.View ArticleGoogle Scholar
- Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020–37.View ArticleGoogle Scholar
- Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7:5577–91.View ArticleGoogle Scholar
- Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomedicine. 2007;2(2):129–41.Google Scholar
- Studenovsky M, Pola R, Pechar M, Etrych T, Ulbrich K, Kovar L, et al. Polymer carriers for anticancer drugs targeted to EGF receptor. Macromol Biosci. 2012;12(12):1714–20.View ArticleGoogle Scholar
- Jeong YI, Kim DH, Chung CW, Yoo JJ, Choi KH, Kim CH, et al. Self-assembled nanoparticles of hyaluronic acid/poly(DL-lactide-co-glycolide) block copolymer. Colloids Surf B: Biointerfaces. 2012;90:28–35.View ArticleGoogle Scholar
- Jeong YI, Seo SJ, Park IK, Lee HC, Kang IC, Akaike T, et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm. 2005;296:151–61.View ArticleGoogle Scholar
- Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3:18496.View ArticleGoogle Scholar
- Qin JM, Yin PH, Li Q, Sa ZQ, Sheng X, Yang L, et al. Anti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma. Int J Nanomedicine. 2012;7:369–79.View ArticleGoogle Scholar
- Wang W, Zhou F, Ge L, Liu X, Kong F. Transferrin-PEG-PE modified dexamethasone conjugated cationic lipid carrier mediated gene delivery system for tumor-targeted transfection. Int J Nanomedicine. 2012;7:2513–22.Google Scholar
- Zhang H, Cai Z, Sun Y, Yu F, Chen Y, Sun B. Folate-conjugated β-cyclodextrin from click chemistry strategy and for tumor-targeted drug delivery. J Biomed Mater Res A. 2012;100:2441–9.Google Scholar
- Yue Y, Eun JS, Lee MK, Seo SY. Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells. Arch Pharm Res. 2012;35:343–9.View ArticleGoogle Scholar
- Gao F, Li L, Liu T, Hao N, Liu H, Tan L, et al. Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects. Nanoscale. 2012;4:3365–72.View ArticleGoogle Scholar
- Zhao P, Wang H, Yu M, Liao Z, Wang X, Zhang F, et al. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2012;81:248–56.View ArticleGoogle Scholar
- Yuen S. Pullulan and its applications. Process Biochem. 1974;9:7–9.Google Scholar
- Jeanes A. Dextrans and pullulans: industrially significant. ACS Symp Ser. 1977;45:284–98.View ArticleGoogle Scholar
- Jeong YI, Na HS, Oh JS, Choi KC, Song CE, Lee HC. Adriamycin release from self-assembling nanospheres of poly(DL-lactide-co-glycolide)-grafted pullulan. Int J Pharm. 2006;322:154–60.View ArticleGoogle Scholar
- Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6:815–23.View ArticleGoogle Scholar
- Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol. 2009;4:855–60.View ArticleGoogle Scholar
- Jung SW, Jeong YI, Kim YH, Kim SH. Self-assembled polymeric nanoparticles of poly(ethylene glycol) grafted pullulan acetate as a novel drug carrier. Arch Pharm Res. 2004;27:562–9.View ArticleGoogle Scholar
- Kim IS, Oh IJ. Preparation and characterization of stearic acid-pullulan nanoparticles. Arch Pharm Res. 2010;33:761–7.View ArticleGoogle Scholar
- Sawada S, Akiyoshi K. Nano-encapsulation of lipase by self-assembled nanogels: induction of high enzyme activity and thermal stabilization. Macromol Biosci. 2010;10:353–8.View ArticleGoogle Scholar
- Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003;55:403–19.View ArticleGoogle Scholar
- Watanabe K, Kaneko M, Maitani Y. Functional coating of liposomes using a folate- polymer conjugate to target folate receptors. Int J Nanomedicine. 2012;7:3679–88.Google Scholar
- Shen X, Li S, Li L, Yao SQ, Xu QH. Highly efficient, conjugated-polymer-based nano-photosensitizers for selectively targeted two-photon photodynamic therapy and imaging of cancer cells. Chemistry. 2014;21:2214–21.View ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.